Has any clinically significant condition or situation (eg, anatomical malformation that complicates intubation) other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.
Has a neuromuscular disorder that may affect NMB and/or trial assessments.
Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min).
Has or is suspected of having a family or personal history of malignant hyperthermia.
Has or is suspected of having an allergy to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia.
Has received or is planned to receive toremifene and/or fusidic acid via IV administration within 24 hours before or within 24 hours after administration of study treatment.
Has been previously treated with sugammadex or has participated in a sugammadex clinical trial.
Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days of signing the informed consent/assent for this current trial.

NCT03351608_exc_T1
Qualifier
clinically significant
NCT03351608_exc_T2
Condition
condition
NCT03351608_exc_T3
Observation
situation
NCT03351608_exc_T4
Qualifier
anatomical malformation
NCT03351608_exc_T5
Negation
other than
NCT03351608_exc_T6
Condition
the condition being studied
NCT03351608_exc_T7
Observation
interfere with the trial evaluations
NCT03351608_exc_T8
Observation
interfere with optimal participation
NCT03351608_exc_T9
Scope
condition or situation (eg, anatomical malformation that complicates intubation)
NCT03351608_exc_T10
Scope
interfere with the trial evaluations or optimal participation
NCT03351608_exc_T11
Condition
neuromuscular disorder
NCT03351608_exc_T12
Observation
affect NMB
NCT03351608_exc_T13
Observation
ffect rial assessments.
NCT03351608_exc_T14
Scope
affect NMB and/or trial assessments
NCT03351608_exc_T15
Condition
dialysis-dependent
NCT03351608_exc_T16
Condition
severe renal insufficiency
NCT03351608_exc_T17
Measurement
estimated glomerular filtration rate (eGFR)
NCT03351608_exc_T18
Value
<30 ml/min
NCT03351608_exc_T19
Scope
severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min)
NCT03351608_exc_T20
Observation
personal history
NCT03351608_exc_T21
Observation
family
NCT03351608_exc_T22
Condition
malignant hyperthermia
NCT03351608_exc_T23
Scope
family or personal history
NCT03351608_exc_T24
Condition
allergy
NCT03351608_exc_T25
Procedure
study treatments
NCT03351608_exc_T27
Drug
opioids
NCT03351608_exc_T28
Drug
opiates
NCT03351608_exc_T29
Drug
muscle relaxants
NCT03351608_exc_T30
Drug
excipients
NCT03351608_exc_T31
Drug
medication
NCT03351608_exc_T32
Qualifier
other
NCT03351608_exc_T33
Procedure
general anesthesia
NCT03351608_exc_T34
Temporal
during general anesthesia
NCT03351608_exc_T26
Drug
excipients
NCT03351608_exc_T35
Scope
study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia
NCT03351608_exc_T36
Drug
toremifene
NCT03351608_exc_T37
Mood
planned to
NCT03351608_exc_T38
Drug
fusidic acid
NCT03351608_exc_T39
Qualifier
IV administration
NCT03351608_exc_T40
Temporal
n 24 hours before or w istration of study treatment.
Has
NCT03351608_exc_T41
Temporal
within 24 hours after administration of study treatment
NCT03351608_exc_T42
Reference_point
administration of study treatment
NCT03351608_exc_T43
Reference_point
administration of study treatment
NCT03351608_exc_T44
Scope
within 24 hours before or within 24 hours after administration of study treatment
NCT03351608_exc_T45
Scope
toremifene and/or fusidic acid
NCT03351608_exc_T46
Drug
sugammadex
NCT03351608_exc_T47
Temporal
previously
NCT03351608_exc_T48
Observation
ipated in a sug al trial.
Is c
NCT03351608_exc_T49
Drug
sugammadex
NCT03351608_exc_T50
Scope
sugammadex or has participated in a sugammadex clinical trial
NCT03351608_exc_T51
Observation
has participated in an interventional clinical trial
NCT03351608_exc_T52
Observation
ly participating in or nterventional clinical trial with a
NCT03351608_exc_T53
Drug
investigational compound
NCT03351608_exc_T54
Device
device
NCT03351608_exc_T55
Temporal
within 30 days of signing the informed consent
NCT03351608_exc_T56
Reference_point
signing the informed consent
NCT03351608_exc_T57
Temporal
30 days of signing the informed consen for th
NCT03351608_exc_T58
Reference_point
 the informed conse for th
NCT03351608_exc_T59
Scope
investigational compound or device
NCT03351608_exc_T60
Scope
currently participating in or has participated in an interventional clinical trial
NCT03351608_exc_T61
Scope
within 30 days of signing the informed consent/assent